var data={"title":"Pentostatin: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Pentostatin: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6372?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=pentostatin-drug-information\" class=\"drug drug_general\">see &quot;Pentostatin: Drug information&quot;</a> and <a href=\"topic.htm?path=pentostatin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Pentostatin: Patient drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5709202\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Experienced physician: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Pentostatin should be administered under the supervision of a physician qualified and experienced in the use of cancer chemotherapeutic agents. </p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Drug toxicities: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">The use of higher doses than those specified is not recommended. Dose-limiting severe renal, liver, pulmonary, and CNS toxicities occurred in Phase 1 studies that used pentostatin at higher doses (20 to 50 mg/m2 in divided doses over 5 days) than recommended.</p>\n        <p style=\"text-indent:-2em;margin-left:2em;\">In a clinical investigation in patients with refractory chronic lymphocytic leukemia using pentostatin at the recommended dose in combination with fludarabine phosphate, 4 of 6 patients entered in the study had severe or fatal pulmonary toxicity. The use of pentostatin in combination with fludarabine phosphate is not recommended.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182953\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Nipent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182954\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Nipent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1030385\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Antineoplastic Agent, Antimetabolite</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antineoplastic Agent, Antimetabolite (Purine Analog)</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Antineoplastic Agent, Antimetabolite (Purine Antagonist)</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1030414\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span><p>(For additional information <a href=\"topic.htm?path=pentostatin-drug-information\" class=\"drug drug_general\">see &quot;Pentostatin: Drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pediatric: <b>Chronic graft-versus-host disease (GVHD), steroid-refractory:</b> Limited data available: Infant, Children, and Adolescents: IV: Initial: 4 mg/m<sup>2</sup> once every 2 weeks; after 6 months of therapy, discontinue for sustained objective response, or continue same dose every 2 to 4 weeks for up to 12 months if still improving (Jacobsohn 2007; Jacobsohn 2009) <b>or</b> 4 mg/m<sup>2</sup> once every 2 weeks for 3 months (Wolff 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adult: <b>Note</b>: Utilize patient's actual body weight (full weight) for calculation of body surface area- or weight-based dosing, particularly when the intent of therapy is curative; manage regimen-related toxicities in the same manner as for nonobese patients; if a dose reduction is utilized due to toxicity, consider resumption of full weight-based dosing with subsequent cycles, especially if cause of toxicity (eg, hepatic or renal impairment) is resolved (Griggs 2012).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Hairy cell leukemia:</b> IV: 4 mg/m<sup>2</sup> every 2 weeks. <b>Note:</b> The optimal duration has not been determined; in the absence of unacceptable toxicity, may continue until complete response is achieved or until 2 doses after complete response. Discontinue after 6 months if partial or complete response is not achieved.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Acute graft-versus-host disease (GVHD), steroid-refractory:</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Initial therapy: 1.5 mg/m<sup>2</sup> days 1 to 3 and days 15 to 17 (in combination with corticosteroids) (Alousi 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Steroid-refractory disease: 1.5 mg/m<sup>2</sup> daily for 3 days; may repeat after 2 weeks if needed (Bolanos-Meade 2005)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <b>Chronic graft-versus-host disease (GVHD), steroid-refractory:</b> IV: 4 mg/m<sup>2</sup> once every 2 weeks; discontinue after 6 months for sustained objective response or continue every 2 to 4 weeks for up to 12 months if still improving (Jacobsohn 2007; Jacobsohn 2009), <b>or</b> 4 mg/m<sup>2</sup> once every 2 weeks for 3 months (Wolff 2011)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment for toxicity: </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants, Children, and Adolescents (Jacobsohn 2007; Jacobsohn 2009; Wolff 2011):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ANC 500 to 1,000/mm<sup>3</sup>: Reduce dose by 25%</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">ANC &lt;500/mm<sup>3</sup>, platelets &lt;20,000/mm<sup>3</sup>, or neutropenic fever: Reduce dose by 50%</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Infection, severe: Interrupt treatment until infection is controlled</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Rash: Severe rashes may require treatment interruption or discontinuation based on experience in adult patients</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Other severe adverse reactions: Withhold treatment or discontinue based on experience in adult patients</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in renal impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling; although not adequately studied, two adult patients with CrCl 50 to 60 mL/minute achieved responses when treated with 2 mg/m<sup>2</sup>/dose. For renal toxicity during treatment, withhold for elevated serum creatinine and determine creatinine clearance. The following adjustments have also been recommended (some are indication specific):</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants, Children, and Adolescents: <b>GVHD treatment</b> (Jacobsohn 2009; Wolff 2011):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl 30 to 50 mL/minute/1.73 m<sup>2</sup>: Reduce dose by 50%</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">CrCl &lt;30 mL/minute/1.73 m<sup>2</sup>: Withhold dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Kintzel 1995: </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 46 to 60 mL/minute: Administer 70% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 31 to 45 mL/minute: Administer 60% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &lt;30 mL/minute: Consider use of alternative drug</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Lathia 2002: </i></p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &ge;60 mL/minute: Administer 4 mg/m<sup>2</sup>/dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 40 to 59 mL/minute: Administer 3 mg/m<sup>2</sup>/dose</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 20 to 39 mL/minute: Administer 2 mg/m<sup>2</sup>/dose</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <i>Alousi 2009; Jacobsohn 2009; Poi 2013</i>: <b>GVHD treatment</b>:</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl 30 to 50 mL/minute/1.73 m<sup>2</sup>: Reduce dose by 50%</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">CrCl &lt;30 mL/minute/1.73 m<sup>2</sup>: Withhold dose</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Dosing adjustment in hepatic impairment:</b> There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182935\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution Reconstituted, Intravenous: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Nipent: 10 mg (1 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182921\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Availability (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1030419\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">At concentrations of 0.18 to 0.33 mg/mL, pentostatin is compatible with PVC containing infusion bags and infusion sets.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">IV: <b>Note:</b> Hydration with fluids prior to pentostatin dose is necessary; in adults, 500 to 1,000 mL fluid prior to dose and 500 mL after dose is recommended per the manufacturer; in one pediatric study 5 mL/kg fluid boluses were given prior to and after the infusion (Jacobsohn 2009).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants, Children, and Adolescents: After further dilution, administer as IV infusion over 20 to 30 minutes (Jacobsohn 2007; Jacobsohn 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: Administer as an IV bolus (2 mg/mL) or as an infusion over 20 to 30 minutes (after further dilution). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132755\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) for preparation. Double gloving, a gown, and (if dosage form allows) CSTDs are required during administration (NIOSH 2016). </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182948\" class=\"block sts drugH1Div\"><span class=\"drugH1\">Storage/Stability</span>\n    <p style=\"text-indent:0em;display:inline\">Store intact vials under refrigeration at 2&deg;C to 8&deg;C (36&deg;F to 46&deg;F). Reconstituted vials and solutions diluted for infusion (in D<sub>5</sub>W or NS) may be stored at room temperature for 8 hours.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1030386\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Treatment (as a single-agent) of untreated and interferon-refractory hairy cell leukemia in patients with active disease (clinically significant anemia, neutropenia, thrombocytopenia, or disease-related symptoms) (FDA approved in adults); has also been used for treatment of cutaneous T-cell lymphoma, chronic lymphocytic leukemia (CLL), and acute and chronic graft-versus-host disease (GVHD) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182988\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Pentostatin may be confused with pentamidine, pentosan</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">Nipent [U.S., Canada, and multiple international markets] may be confused with Nipin brand name for nifedipine [Italy, Singapore]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182985\" class=\"block arm drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Central nervous system toxicity, chills, fatigue, headache, pain</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiovascular: Angina pectoris, atrioventricular block, bradycardia, cardiac arrhythmia, cardiac failure, chest pain, deep vein thrombophlebitis, facial edema, hypertension, hypotension, localized phlebitis, pericardial effusion, peripheral edema, sinoatrial arrest, syncope, tachycardia, vasculitis, ventricular premature contractions</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Central nervous system: Abnormal dreams, abnormality in thinking, amnesia, anxiety, ataxia, confusion, depression, dizziness, drowsiness, dysarthria, emotional lability, encephalitis, hallucination, hostility, insomnia, meningism, nervousness, neuralgia, neuritis, neuropathy, paralysis, paresthesia, psychoneurosis, seizure, twitching, vertigo</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Acne vulgaris, alopecia, cellulitis, diaphoresis, eczema, furunculosis, pruritus, skin changes, skin photosensitivity, skin rash, urticaria, xeroderma</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Endocrine &amp; metabolic: Amenorrhea, decreased libido, hypercalcemia, hyponatremia, gout, loss of libido</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal pain, anorexia, constipation, diarrhea, dysgeusia, dyspepsia, dysphagia, flatulence, gingivitis, glossitis, intestinal obstruction, nausea, oral candidiasis, stomatitis, vomiting</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Genitourinary: Impotence, urinary tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hematologic &amp; oncologic: Acute leukemia, agranulocytosis, anemia, aplastic anemia, bone marrow depression (nadir: 7 days; recovery: 10 to 14 days), hemolytic anemia, hemorrhage, leukopenia, petechia, thrombocytopenia</p>\n    <p style=\"text-indent:0em;\">Hepatic: Increased serum transaminases</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity: Hypersensitivity reaction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Infection: Abscess, bacterial infection, herpes simplex infection, herpes zoster, infection, sepsis, viral infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Neuromuscular &amp; skeletal: Arthralgia, arthritis, hyperkinesia, myalgia, osteomyelitis, weakness</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ophthalmic: Amblyopia, conjunctivitis, lacrimal dysfunction, nonreactive pupils, photophobia, retinopathy, visual disturbance, watery eyes, xerophthalmia</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Otic: Deafness, labyrinthitis, otalgia, tinnitus</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal: Increased serum creatinine, nephrolithiasis, renal disease, renal failure, renal function abnormality, renal insufficiency</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Respiratory: Asthma, bronchitis, bronchospasm, cough, dyspnea, flu-like symptoms, laryngeal edema, pharyngitis, pneumonia, pulmonary embolism, rhinitis, sinusitis, upper respiratory tract infection</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Miscellaneous: Fever</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Rare but important or life-threatening: Dysuria, fungal skin infection, hematuria, lethargy, pulmonary edema, pulmonary toxicity (in combination with fludarabine), uveitis, vision loss</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182941\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Hypersensitivity to pentostatin or any component of the formulation </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182925\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Bone marrow suppression: Myelosuppression may occur, primarily early in treatment (first few courses). Neutropenia may worsen during initial courses for the treatment of hairy cell leukemia. If severe neutropenia persists beyond early cycles, evaluate for disease status. Monitor blood counts during treatment (more frequently in the initial cycles).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; CNS toxicity: <b>[U.S. Boxed Warnings]: Severe CNS toxicities have occurred with doses higher than recommended; do not exceed the recommended dose. </b>Withhold treatment or discontinue for CNS toxicity.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Hepatotoxicity: <b>[U.S. Boxed Warnings]: Severe liver toxicities have occurred with doses higher than recommended; do not exceed the recommended dose.  </b>May cause elevations (usually reversible) in liver function tests.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Pulmonary toxicity: <b>[U.S. Boxed Warnings]: Severe pulmonary toxicities have occurred with doses higher than recommended; do not exceed the recommended dose.  Do not administer concurrently with fludarabine; concomitant use has resulted in serious or fatal pulmonary toxicity. </b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Rash: Severe rashes may occur and worsen with therapy continuation; may require treatment interruption or discontinuation. </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal toxicity: <b>[U.S. Boxed Warnings]: Severe renal toxicities have occurred with doses higher than recommended; do not exceed the recommended dose.</b> Serum creatinine elevations occurring at recommended doses are usually minor and reversible. Withhold treatment for elevated serum creatinine and determine creatinine clearance. May require dosage adjustment or therapy discontinuation.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Infections: In patients who present with infections prior to treatment, infections should be resolved, if possible, prior to initiation of treatment; preexisting infections may worsen with pentostatin treatment. Treatment should be temporarily withheld for active infections during therapy. Use in patients with infections only if the potential benefit justifies the potential risk.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Renal impairment: Use with caution in patients with renal dysfunction (CrCl &lt;60 mL/minute); the terminal half-life is prolonged; may require dosage adjustment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information. Concurrent use with fludarabine has resulted in severe or fatal pulmonary toxicity and is not recommended. Fatal pulmonary edema and hypotension have been reported in patients treated with pentostatin in combination with carmustine, etoposide, or high-dose cyclophosphamide as part of a myeloablative regimen for bone marrow transplant.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&bull; Experienced physician: <b>[U.S. Boxed Warning]: Should be administered under the supervision of an experienced cancer chemotherapy physician.</b></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299851\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182930\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=13016&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cyclophosphamide: Pentostatin may enhance the cardiotoxic effect of Cyclophosphamide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fludarabine: May enhance the adverse/toxic effect of Pentostatin. Pentostatin may enhance the adverse/toxic effect of Fludarabine. Pulmonary toxicity is of specific concern.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nelarabine: Pentostatin may diminish the antineoplastic effect of Nelarabine. Conversion of nelarabine, a pro-drug, to its active form may be inhibited by pentostatin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pegademase Bovine: Pentostatin may diminish the therapeutic effect of Pegademase Bovine. Pegademase Bovine may diminish the therapeutic effect of Pentostatin. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the neutropenic effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182943\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Adverse events were observed in animal reproduction studies. Women of childbearing potential should be advised to avoid becoming pregnant during treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5994363\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\"> CBC with differential and platelet count (prior to each dose; more frequently during initial cycles), peripheral blood smears (periodically for hairy cells and to assess treatment response), liver function, serum uric acid, renal function (serum creatinine and/or creatinine clearance at baseline, and serum creatinine prior to each dose), bone marrow evaluation, signs/symptoms of pulmonary and CNS toxicity</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182924\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Pentostatin is a purine antimetabolite that inhibits adenosine deaminase, preventing the deamination of adenosine to inosine. Accumulation of deoxyadenosine (dAdo) and deoxyadenosine 5&prime;-triphosphate (dATP) results in a reduction of purine metabolism which blocks DNA synthesis and leads to cell death.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182940\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: IV: 20 L/m<sup>2</sup> (Lathia, 2002)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: ~4%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Terminal: ~6 hours; Renal impairment (CrCl &lt;50 mL/minute): 18 hours (range: 11 to 23 hours [Lathia, 2002])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (~50% to 96%) within 24 hours (30% to 90% as unchanged drug) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Clearance: Adults: 68 mL/minute/m<sup>2</sup> (mean) </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323197\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution (reconstituted)</b> (Nipent Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg (1): $2,647.57</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F182944\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Nipent (BB, BE, DE, ES, FR, GB, GR, IE, IT, KR, NL)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    al-Razzak LA, Benedetti AE, Waugh WN, et al, &ldquo;Chemical Stability of Pentostatin (NSC-218321), a Cytotoxic and Immunosuppressant Agent,&rdquo; <i>Pharm Res</i>, 1990, 7(5):452-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentostatin-pediatric-drug-information/abstract-text/2367313/pubmed\" target=\"_blank\" id=\"2367313\">2367313</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Alousi AM, Weisdorf DJ, Logan BR, et al. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. <i>Blood</i>. 2009;114(3):511-517.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentostatin-pediatric-drug-information/abstract-text/19443659/pubmed\" target=\"_blank\" id=\"19443659\">19443659</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bolanos-Meade J, Jacobsohn DA, Margolis J, et al, &ldquo;Pentostatin in Steroid-Refractory Acute Graft-Versus-Host Disease,&rdquo; <i>J Clin Oncol</i>, 2005, 23(12):2661-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentostatin-pediatric-drug-information/abstract-text/15837980/pubmed\" target=\"_blank\" id=\"15837980\">15837980</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Brogden RN and Sorkin EM, &ldquo;Pentostatin. A Review of Its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Potential in Lymphoproliferative Disorders,&rdquo; <i>Drugs</i>, 1993, 46(4):652-77. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentostatin-pediatric-drug-information/abstract-text/ 7506651 /pubmed\" target=\"_blank\" id=\" 7506651 \"> 7506651 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Bubalo J, Carpenter PA, Majhail N, et al. Conditioning chemotherapy dose adjustment in obese patients: a review and position statement by the American Society for Blood and Marrow Transplantation practice guideline committee. <i>Biol Blood Marrow Transplant</i>. 2014;20(5):600-616. doi: 10.1016/j.bbmt.2014.01.019.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentostatin-pediatric-drug-information/abstract-text/24462742/pubmed\" target=\"_blank\" id=\"24462742\">24462742</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Catovsky D, &ldquo;Clinical Experience With 2&prime;-Deoxycoformycin,&rdquo; <i>Hematol Cell Ther</i>, 1996, 38(Suppl 2):103-7. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentostatin-pediatric-drug-information/abstract-text/9137963/pubmed\" target=\"_blank\" id=\"9137963\">9137963</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dillman RO, &ldquo;A New Chemotherapeutic Agent: Deoxycoformycin (Pentostatin),&rdquo; <i>Semin Hematol</i>, 1994, 31(1):16-27. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentostatin-pediatric-drug-information/abstract-text/8122134/pubmed\" target=\"_blank\" id=\"8122134\">8122134</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dillman RO, Mick R, and McIntyre OR, &ldquo;Pentostatin in Chronic Lymphocytic Leukemia: A Phase II Trial of Cancer and Leukemia Group B,&rdquo; <i>J Clin Oncol</i>, 1989, 7(4):433-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentostatin-pediatric-drug-information/abstract-text/2784491/pubmed\" target=\"_blank\" id=\"2784491\">2784491</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Grever MR, Siaw MFE, Jacob WF, et al, &ldquo;The Biochemical and Clinical Consequences of 2'-Deoxycoformycin in Refractory Lymphoproliferative Malignancy,&rdquo;<i> Blood</i>, 1981, 57(3):406-17.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentostatin-pediatric-drug-information/abstract-text/6970050/pubmed\" target=\"_blank\" id=\"6970050\">6970050</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Griggs JJ, Mangu PB, Anderson H, et al, &ldquo;Appropriate Chemotherapy Dosing For Obese Adult Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline,&rdquo;<i> J Clin Oncol</i>, 2012, 30(13):1553-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentostatin-pediatric-drug-information/abstract-text/22473167/pubmed\" target=\"_blank\" id=\"22473167\">22473167</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jacobsohn DA, Chen AR, Zahurak M, et al, &ldquo;Phase II Study of Pentostatin in Patients With Corticosteroid-Refractory Chronic Graft-Versus-Host Disease,&rdquo; <i>J Clin Oncol</i>, 2007, 25(27):4255-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentostatin-pediatric-drug-information/abstract-text/17878478/pubmed\" target=\"_blank\" id=\"17878478\">17878478</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jacobsohn DA, Gilman AL, Rademaker A, et al. Evaluation of pentostatin in corticosteroid-refractory chronic graft-versus-host disease in children: a Pediatric Blood and Marrow Transplant Consortium study. <i>Blood</i>. 2009;114(20):4354-4360.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentostatin-pediatric-drug-information/abstract-text/19745067/pubmed\" target=\"_blank\" id=\"19745067\">19745067</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kane BJ, Kuhn JG, and Roush MK, &ldquo;Pentostatin: An Adenosine Deaminase Inhibitor For the Treatment of Hairy Cell Leukemia,&rdquo; <i>Ann Pharmacother</i>, 1992, 26(7-8):939-47. <span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentostatin-pediatric-drug-information/abstract-text/1504408/pubmed\" target=\"_blank\" id=\"1504408\">1504408</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kintzel PE and Dorr RT, &ldquo;Anticancer Drug Renal Toxicity and Elimination: Dosing Guidelines for Altered Renal Function,&rdquo; <i>Cancer Treat Rev</i>, 1995, 21(1):33-64.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentostatin-pediatric-drug-information/abstract-text/7859226/pubmed\" target=\"_blank\" id=\"7859226\">7859226</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kurzrock R, Pilat S, and Duvic M, &ldquo;Pentostatin Therapy of T-Cell Lymphomas With Cutaneous Manifestations,&rdquo; <i>J Clin Oncol</i>, 1999, 17(10):3117-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentostatin-pediatric-drug-information/abstract-text/10506607/pubmed\" target=\"_blank\" id=\"10506607\">10506607</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Lathia C, Fleming GF, Meyer M, et al, &ldquo;Pentostatin Pharmacokinetics and Dosing Recommendations in Patients With Mild Renal Impairment,&rdquo; <i>Cancer Chemother Pharmacol</i>, 2002, 50(2):121-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentostatin-pediatric-drug-information/abstract-text/12172976/pubmed\" target=\"_blank\" id=\"12172976\">12172976</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Margolis J and Grever MR, &quot;Pentostatin (Nipent): A Review of Potential Toxicity and Its Management,&quot; <i>Semin Oncol</i>, 2000, 27(2 Suppl 5):9-14.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentostatin-pediatric-drug-information/abstract-text/10877045/pubmed\" target=\"_blank\" id=\"10877045\">10877045</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nipent (pentostatin) (prescribing information). Lake Forest, Il: Hospira, Inc; April 2009</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Poi MJ, Hofmeister CC, Johnston JS, et al. Standard pentostatin dose reductions in renal insufficiency are not adequate: selected patients with steroid-refractory acute graft-versus-host disease. <i>Clin Pharmacokinet</i>. 2013;52(8):705-712.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentostatin-pediatric-drug-information/abstract-text/23588536/pubmed\" target=\"_blank\" id=\"23588536\">23588536</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tsimberidou AM, Giles F, Duvic M, et al, &ldquo;Phase II Study of Pentostatin in Advanced T-Cell Lymphoid Malignancies: Update of an M.D. Anderson Cancer Center Series,&rdquo; <i>Cancer</i>, 2004, 100(2):342-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentostatin-pediatric-drug-information/abstract-text/14716770/pubmed\" target=\"_blank\" id=\"14716770\">14716770</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Wolff D, Schleuning M, von Harsdorf S, et al. Consensus Conference on Clinical Practice in Chronic GVHD: Second-Line Treatment of Chronic Graft-versus-Host Disease. <i>Biol Blood Marrow Transplant</i>. 2011;17(1):1-17.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/pentostatin-pediatric-drug-information/abstract-text/20685255/pubmed\" target=\"_blank\" id=\"20685255\">20685255</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 13016 Version 126.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5709202\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F182953\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F182954\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1030385\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1030414\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F182935\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Availability (US)\" href=\"#F182921\" class=\"outlineLink\">Generic Availability (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1030419\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132755\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Storage/Stability\" href=\"#F182948\" class=\"outlineLink\">Storage/Stability</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1030386\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F182988\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F182985\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F182941\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F182925\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299851\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F182930\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F182943\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F5994363\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F182924\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F182940\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323197\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F182944\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/13016|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=pentostatin-drug-information\" class=\"drug drug_general\">Pentostatin: Drug information</a></li><li><a href=\"topic.htm?path=pentostatin-patient-drug-information\" class=\"drug drug_patient\">Pentostatin: Patient drug information</a></li></ul></div></div>","javascript":null}